Requested a meeting with ADM Moneo to share details of the UK NHS program addressing Cardiovascular Disease (CVD) on a population wide basis as might be applied within a BC specific program should BC's Ministry of Health see value in adopting this approach.
In 2020 UK’s NHS (England) announced a program to identify patients at high-risk for CVD, and provide intensive treatment for these patients with the objectives of 1) reducing morbidity & mortality caused by CVD and 2) reducing overall costs associated with this disease. The NHS program is being implemented as a result of an innovative agreement between the NHS and Novartis Pharmaceuticals.
Background: According to the March 11th, 2021 Health Ministry report ‘Covid-19 in BC’ - Heart Disease is the second leading cause of death and the third leading cause of potential years of life lost in BC.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health, Hospitals
|